Olema Oncology
San Francisco · Founded 2006
About Olema Oncology
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.
Company Facts
- Founded: 2006
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $50K – $100K
- Total funding: $765.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Nov 2025)
- Ticker: nasdaq:OLMA
- Website: https://olema.com
- Phone: 4157428265
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/olema-oncology-40900 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.